Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(42.9%)

N/A

2(28.6%)

Phase 4

2(28.6%)

7Total

Phase 1(3)

N/A(2)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04997681Not ApplicableCompleted

SYNchronizing Exercises, Remedies in Gait and Cognition at Home (SYNERGIC@Home)

Role: collaborator

NCT03618368Not ApplicableUnknown

Second Clinical Evaluation of THERANOVA-500 Dialyzer in Chronic Hemodialysis (HD)

Role: lead

NCT03576625Phase 1Unknown

Effect of Buglossoides Oil on Recent Chronic Non-injurious Hip and Knee Pain

Role: lead

NCT03390712Unknown

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Role: lead

NCT02537990Unknown

MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank

Role: collaborator

NCT02540759Phase 1Completed

Effect of Dose of Buglossoides Oil on EPA Accrual and on the Inflammatory Response

Role: lead

NCT02226354Phase 1Completed

Study of the Safety and Efficacy of Dietary Buglossoides Oil

Role: lead

NCT01326351Phase 4Unknown

Prolotherapy for the Treatment of Plantar Fasciitis

Role: lead

NCT01206634Phase 4Completed

Regenerative Injection Therapy and Osteoarthritis

Role: lead

All 9 trials loaded